The in vitro activity of the antifungal agents amphotericin B (AMB), itraconazole (ITC), posaconazole (PSC), voriconazole (VRC), and terbinafine (TRB) against 32 Brazilian isolates of Sporothrix brasiliensis, including 16 isolates from a recent (2011-2012) epidemic in Rio de Janeiro state, was examined. We describe and genotype new isolates and clustered them with 16 older (from 2004 or earlier) S. brasiliensis isolates by phylogenetic analysis. We tested both the yeast and the mycelium form of all isolates using broth microdilution methods based on the reference protocols M38-A2 and M27-A3 (recommended by the Clinical and Laboratory Standards Institute). Considering minimum inhibitory concentrations (MICs) and minimum fungicidal concentrations (MFCs), TRB was found to be the most active drug in vitro for both fungal forms, followed by PSC. Several isolates showed high MICs for AMB and/or ITC, which are currently used as firstline therapy for sporotrichosis. VRC displayed very low activity against S. brasiliensis isolates. The primary morphological modification observed on treated yeasts by transmission electron microscopy analysis was changes in cell wall. Our results indicate that TRB is the antifungal with the best in vitro activity against S. brasiliensis and support the use of TRB as a promising option for the treatment of cutaneous and/or lymphocutaneous sporotrichosis.
Introduction
The Sporothrix schenckii complex is a group of several cryptic species of dimorphic fungi that cause sporotrichosis, a disease with a worldwide distribution [1] [2] [3] . Sporotrichosis is acquired by traumatic inoculation into the skin of the filamentous form of the fungus, which is present in soil and vegetation, or by scratches, bites, or direct contact with lesion secretion of contaminated animals, where yeasts are the infective form [4] . The clinical spectrum of sporotrichosis includes cutaneous, lymphocutaneous, invasive (to internal organs), and disseminated forms [4] .
Clinical isolates of sporotrichosis are often represented by several cryptic species from the S. schenckii complex, which includes S. brasiliensis (clade I), S. schenckii sensu stricto (clade II), S. globosa (clade III), S. mexicana (clade IV), S. pallida (clade V), and S. luriei (clade VI) [3] . Sporothrix brasiliensis is clearly the most virulent species in animal models, causing rapid tissue invasion and high mortality rates [5] [6] [7] . It is also the predominant species in the current epidemic of sporotrichosis in the Brazilian state of Rio de Janeiro [8] [9] [10] .
The first-line treatment for lymphocutaneous and cutaneous sporotrichosis is itraconazole (ITC) [11] . However, reports of isolates insensitive to ITC in vitro are increasing [12] [13] [14] [15] [16] . Likewise, cases of sporotrichosis unresponsive to ITC have been reported [17] [18] [19] [20] . Terbinafine (TRB) is the second-line treatment for lymphocutaneous and cutaneous sporotrichosis [11] , while amphotericin B (AMB) alone is commonly used for the treatment of invasive and disseminated forms [11] . Among the extended-spectrum azoles, voriconazole (VRC) is not active against S. schenckii sensu lato [13, 15, 16, 21, 22] , whereas posaconazole (PSC) has good in vitro activity [14, 21, 22] .
Recent phylogenetic studies on new Sporothrix species from clinical isolates have provided an explanation for important differences in the epidemiology, pathogenesis, and treatment of sporotrichosis. Over the last two decades, S. brasiliensis emerged as a clonal genotype during a zoonotic outbreak [9, 10] , causing a large-scale epidemic, with various cases in humans and felines in the metropolitan region of Rio de Janeiro city [1, 8, 9, 23] . To date, few studies have examined the antifungal susceptibility profile of Sporothrix species as defined by the most recent phylogenetic data [15, 16, 21] ; most studies on Sporothrix drug sensitivity were performed using isolates that are known to represent mixtures of cryptic Sporothrix species [12] [13] [14] 20, 22, 24, 25] . In particular, the limited number of studies that evaluated the drug sensitivity of S. brasiliensis used the filamentous (mycelium) form of the fungus [16, 21] , although yeast is the main morphology present in the host, probably due to the technically challenging in vitro differentiation to the yeast form.
Our aim in this study was to evaluate the susceptibility of S. brasiliensis isolates (in both mycelium and yeast forms) to currently used agents for the treatment of sporotrichosis (ITC, AMB, and TRB), as well to extended-spectrum azoles (PSC and VRC) used clinically against fungal infections. Additionally, we analyzed the ultrastructural alterations observed in treated yeasts using transmission electron microscopy (TEM).
Materials and methods

Fungal isolates
The 32 isolates of S. brasiliensis tested in this study were recovered from humans (n = 29), felines (n = 2), and the environment (n = 1) in the Brazilian states of Rio de Janeiro (n = 24), Rio Grande do Sul (n = 3), Minas Gerais (n = 2), Paraná (n = 2), and São Paulo (n = 1). These isolates formed two groups of 16 strains, with one group representing new isolates (2011-2012) described here for the first time and the other 16 strains representing previously described isolates collected before 2004.
Sporothrix brasiliensis isolates from 2004 and earlier included the genome strain American Type Culture Collection (ATCC) MYA-4823 (5110), reference strains ATCC MYA-4824 (IPEC 17943), and FMR 8337 [26] , and 13 isolates collected between 2003 and 2004 (Ss07, Ss14, Ss34, Ss37, Ss52, Ss54, Ss56, Ss57, Ss68, Ss69, Ss72, Ss81, Ss82) that have been maintained in culture ever since [9, 26] . Five of these isolates (Ss68, Ss69, Ss72, Ss81, and Ss82) were collected at the Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil . The 16 newer isolates  (B70, B91, B182, B198, B204, B428, B435, B628, B735,  B758, B818, B848, B972, B1008, B1036, HE06) were collected between 2011 and 2012 at the HUCFF and were genotyped as S. brasiliensis, as described below.
All isolates were stored on potato dextrose agar (PDA; Difco, Detroit, MI, USA) plates at −4
• C. For microdilution tests, mycelium forms were cultivated at room temperature on PDA slants for 7 days. The yeast phase was obtained by two successive passages on brain heart infusion (Difco) broth supplemented with 2% glucose, each passage consisting of incubation at 36 o C, with orbital agitation for 7 days.
Antifungal drugs
AMB, ITC, PSC, VRC, and TRB (Sigma-Aldrich, Co, St. Louis, MO, USA) and kept as 1600-µg/ml stock solutions in dimethyl sulfoxide at −70 • C.
Genotyping
Total DNA from Sporothrix spp. isolates was purified directly from fungal mycelium colonies using the Fast DNA kit (MP Biomedicals, USA). We amplified and sequenced 800 pb of the calmodulin gene (CAL) corresponding to exons 3 to 5 using the degenerate primers CL1 (5 -GAR TWC AAG GAG GCC TTC TC) and CL2A (5 -TTT TTG CAT CAT GAG TTG GAC), as described previously [27] . Forward and reverse sequence reads were assembled into single sequences using the online toll CAP3 and considering bases with Phred ≥30. Sequence alignments were performed using MAFFT v6 [28] [9] , and Rodrigues et al. [23] . Evolutionary analyses were conducted in MEGA5 [29] using maximum likelihood (ML) and neighbor-joining (NJ) methods. Genetic distances were estimated using a Kimura 2-parameter method [30] , with 1000 bootstrap replicates [31] .
Minimum inhibitory concentration determination
Susceptibility tests were performed using microdilution techniques based on the Clinical and Laboratory Standards Institute (CLSI) protocols M27-A3 (for the yeast form) [32] and M38-A2 (for the mycelium form) [33] . These reference protocols were adapted for use with dimorphic fungi by increasing the incubation period to five days in order to compensate for the sluggish growth of the different Sporothrix spp. in vitro [12, 24, 25] . Furthermore, as Sporothrix yeasts grow slower than mycelia, glucose was added to the Roswell Park Memorial Institute (RPMI) 1640 medium for experiments that used the yeast forms in order to increase yeast growth during experimental incubations. Briefly, the compounds were diluted in RPMI 1640 medium buffered at pH 7.2 with 0.165 M 3-(N-morpholino) propane sulfonic acid (supplemented yeast assays) or not (mycelium assays) with 2% glucose into 96-well plates to obtain final concentrations of 0.01-16 µg/ml of each drug. Then, 100 µl of fungal suspension was dispensed into each well for a final yeast cell density of 0.5-2.5 × 10 3 colony forming units (CFU)/ml or conidial suspension density of 0.5-2.5 × 10 4 CFU/ml. Samples were incubated at 35
• C for five days in the dark in a humid chamber with 5% CO 2 . Minimum drug concentrations that inhibited approximately 90% of fungal growth relative to controls (minimum inhibitory concentrations [MICs]) were determined by visual inspection in an inverted optical microscope (Axiovert 100, Zeiss).
Minimum fungicidal concentration determination
Minimum fungicidal concentrations (MFCs) were determined by spreading 10 µl of each sample treated with drug concentrations equal to and greater than the MIC (and up to 16 µg/ml) on a drug-free PDA plate. Then, plates were incubated at 35
• C for seven days; the MFC was defined as the lowest drug concentration failing to produce fungal growth. Following guidelines presented by Pfaller et al. [34] , we referred to a drug as "fungicidal" if its MFC was greater than or equal to fourfold higher than the MIC. If the MFC was greater than fourfold higher than the MIC, the antifungal effect was considered "fungistatic." 
Transmission electron microscopy
Results
Molecular identification revealed that all new strains were S. brasiliensis
To genotype the Sporothrix isolates collected in Rio de Janeiro state between 2011 and 2012, the CAL from these isolates was sequenced and used to build a phylogenetic tree ( Fig. 1 ; reproduced in color as Supplementary Figure 1) . The phylogenetic tree revealed that all strains recently recovered from patients involved in the zoonotic epidemic in Rio de Janeiro belonged to S. brasiliensis and clustered together with the type strain of S. brasiliensis (CBS 120339) in a single-branch well supported by high bootstrap values (98/85; Fig. 1 ). Similar tree topologies were produced by NJ and ML analyses (P = 1.63e-18) [35] .
TRB and PSC were the most effective antifungal agents against S. brasiliensis
MICs and MFCs for 32 S. brasiliensis isolates in mycelium and yeast forms are shown in Tables 1 and 2, respectively  (see also Supplementary Tables 1 and 2 ). TRB and PSC showed good activity against all isolates; nevertheless, TRB showed the lowest MICs (geometric mean of 0.1 µg/ml). AMB showed high MICs against 1 isolate in mycelium form (1/32; MIC = 8 µg/ml) and 10 in the yeast form (10/32; MICs = 4 µg/ml). In addition, ITC showed high MICs (≥4 µg/ml) against several isolates in both mycelium (12/32) and yeast forms (9/32). All isolates in both forms showed high MICs for VRC (0.5-16 µg/ml). Importantly, when recent (2011-2012) and older isolates were compared, ITC and PSC were less potent against yeasts from the recent isolates than the older isolates (P = 0.005 and P = 0.0097, respectively). In addition, PSC was less active against mycelium forms of these isolates (P = 0.0005). Figure 2 shows the comparison between antifungal MICs for mycelium and yeast forms of the new and older S. brasiliensis isolates. TRB was the most effective antifungal agent against both fungal forms since its MICs were considerably lower than those for the other drugs, with little variation in MICs between isolates. PSC was the second most effective antifungal followed by AMB, ITC, and VRC. Statistically significant differences between mycelium and yeast MICs were detected only for VRC, which was more active against the yeast of older isolates (P = 0.0023), and for AMB, which was more active against mycelium of new isolates (Fig. 2) .
MFC values for both the mycelium and the yeast forms indicated that AMB, PSC, VRC, and TRB display primarily a fungicidal activity profile against recent and older S. brasiliensis isolates ( Table 2 ). In contrast, ITC has a fungistatic activity profile.
Treatment of S. brasiliensis with antifungals induces cell wall alterations
To verify if antifungal treatments performed here had induced ultrastructural alterations, we visualized yeasts of S. brasiliensis ATCC MYA 4023 by transmission electron microscopy after 24-h treatments with subinhibitory concentrations of AMB, ITC, or TRB, the drugs most commonly used for sporotrichosis treatment.
Untreated yeast cells of S. brasiliensis ATCC MYA 4023 displayed a regular cell wall (CW * ), with a compact outermost microfibrillar layer (Fig. 3A) . The cell membrane surrounded homogeneous and electron-dense cytoplasm containing nucleus, mitochondria, and vacuoles, all with expected morphology and distribution (Fig. 3A, B) . Sporothrix brasiliensis yeasts treated with 0.25 µg/ml of AMB or ITC displayed electron lucent vacuoles (Fig.  3 C, E, F) and several vesicles close to the cell wall (arrows in Fig. 3D, F) . No clear changes in yeast ultrastructure were observed after treatment with 0.015 µg/ml TRB (Fig. 3G, H) .
We detected a statistically significant difference in the thickness of cell wall components (the microfibrillar outermost layer and the cell wall proper [CW * ]), as indicated in Fig. 3B , after drug treatment (Fig. 3I) . ITC treatment increased microfibrillar layer thickness, AMB treatment increased CW * thickness, and TRB treatment reduced CW * thickness (Fig. 3I) . Compared with its sister taxa S. schenckii sensu stricto, the species S. brasiliensis displays low genetic diversity, with only a few haplotypes involved in human and animal outbreaks [9, 10] . The low genetic variation in phylogenetic analysis is also supported by low chromosome polymorphism in S. brasiliensis [36] . All isolates collected between * P < 0.05, * * P < 0.001, * * * P < 0.0001.
2011 and 2012 from Rio de Janeiro state were identified as S. brasiliensis and clustered together in a single branch of the phylogenetic tree, with high bootstrap values (Fig. 1) . These results reinforce the high prevalence of sporotrichosis caused by S. brasiliensis in Rio de Janeiro state, as previously reported [8, 9] . The possible emergence of a virulent clonal S. brasiliensis haplotype may have severe implications for disease management, highlighting the importance of defining the drug-sensitivity profile of recent isolates of this pathogenic fungus. Regarding the microdilution testes performed, we felt it necessary to adapt the CLSI protocols M27-A3 and M38-A2 for S. brasiliensis. Previous studies on Sporothrix spp. microdilution tests have also used modified CLSI protocols, changing parameters such as medium, time, and temperature of incubation [12] [13] [14] [20] [21] [22] 24, 25, 37] . In the present study, an important modification was the addition of 2% glucose to the RPMI 1640 medium when performing yeast assays; this was done because some isolates did not grow well in standard RPMI 1640 medium. Additionally, the incubation time was extended to five days due to the slow growth of the fungus. We concluded that it is also important to perform microdilution tests using the yeast phase of dimorphic fungi, considering that mycelium and yeast may have different susceptibility profiles to antifungal agents. Thus, the traditional extrapolation to infective yeast forms of drug susceptibility results obtained using saprophytic mycelium forms should be performed with caution. Thus, a standard microdilution test for dimorphic fungi, such as Sporothrix spp., must be implemented. For Paracoccidioides brasiliensis, another dimorphic fungi, a microdilution assay protocol was proposed by Cruz et al. [38] , modified from the M27-A3 document.
Interestingly, the antifungal drugs used as first-line treatment for sporotrichosis (ITC and AMB) exhibited high MICs for S. brasiliensis isolates (Table 1) . There are few studies of the correlation between in vivo therapeutic response and the in vitro antifungal susceptibility assay of S. schenckii sensu lato, and this subject is still very controversial [37, 39] . Additionally, MIC breakpoints have not been established for the S. schenckii complex in mycelium or yeast phases; therefore, it is not possible to determine if some isolate is resistant or susceptible. However, MICs ≤2 µg/ml or ≥4 µg/ml might indicate susceptibility or resistance, respectively, for some filamentous and yeast fungi [32, 33] . We observed that TRB was the antifungal drug with the best overall in vitro activity against S. brasiliensis (Table 1, Fig. 2) , as shown by the lowest MICs within the panel of drugs tested (geometric mean MIC value = 0.1 µg/ml; Table 1 ). Previous studies also showed that TRB had better activity than AMB and ITC against S. schenckii sensu lato [12, 14, 22, 24, 25] and S. brasiliensis in mycelium form [16, 21] . Successful outcomes of sporotrichosis treated with TRB have been reported in the cutaneous and lymphocutaneous forms of the disease [40] [41] [42] , including cases where therapy with ITC was unsuccessful [20, 43] . Furthermore, topical formulations of TRB have shown good results against dermatophytes [44] ; thus, topical TRB treatment could be used in combination with oral treatment against sporotrichosis.
According to CLSI protocols M27-A2 and M38-A2, experience to date with PSC and VRC indicates that MICs vary between 0.03 µg/ml and 16 µg/ml, with the majority of isolates inhibited by <1 µg/ml for both antifungal agents, including Candida spp. and Aspergillus spp. However, there are no reports available to date on the correlation between MICs and treatment outcomes for these antifungal agents.
In our work, most isolates had MICs ≥2 µg/ml for VRC. In contrast, PSC showed good activity against most S. brasiliensis isolates, with MICs ≤1 µg/ml (Supplementary Table 1 ), which is in agreement with previous studies [14, 21, 22] . However, some recent isolates (34%) displayed higher MICs (≥1 µg/ml) for PSC.
A previous in vivo study showed reduction in fungal load after treatment with two daily doses of 2.5 or 5 mg/kg of PSC in a murine model of disseminated sporotrichosis caused by S. brasiliensis [39] . Unfortunately, PSC
is not yet available in Brazil, although it is commercially available and approved for clinical use in many other countries. Additionally, the high costs of PSC treatment make it an unfeasible alternative to the current first-line therapy.
For S. brasiliensis mycelium assays, we observed mean MICs for AMB and TRB that were similar to those reported by Marimon et al. [21] (1.67 µg/ml and 0.09 µg/ml for AMB and TRB, respectively). In contrast, the mean MICs for ITC shown here were higher than previously reported by Marimon et al. [21] (0.7 µg/ml). Interestingly, for all drugs, MICs obtained for newer S. brasiliensis isolates were generally higher than those for older isolates. The fact that the new isolates were less susceptible to tested antifungals than to isolates maintained in the laboratory should be further investigated. Nevertheless, the emergence of clinical isolates with reduced in vitro susceptibility to AMB and ITC is alarming. Overexpression of plasma membrane efflux pumps is a known mechanism for resistance antifungals, and ATP-binding cassette (ABC) transporters are one of the efflux protein families [45] . In Fonsecaea pedrosoi, it was shown that a recently isolated clinical strain exhibited low susceptibility to itraconazole and express higher levels of ABC transporter compared with a laboratory strain and that its expression was increased when fungus was continuously exposed to this antifungal [46] . VRC displayed very low activity in vitro against S. brasiliensis, which is in agreement with previous in vitro [16, 21] and in vivo [7] studies on the response of S. brasiliensis to VRC treatment.
Another important finding described here is the in vitro fungicidal activity profile exhibited by PSC, VRC, and TRB. Based on the MICs and MFCs reported by Ottonelli et al. [16] , TRB did exhibit a fungicidal activity profile against some S. brasiliensis isolates tested in the mycelium phase (MFC ≤ 4 × MIC); however, these authors reported a fungistatic activity profile only (MFC ≤ 4 × MIC) for ITC and VRC [16] .
It is difficult to demonstrate the microbiocidal nature of an antimicrobial agent [34] . MFCs do not represent the most accurate measure of microbiocidal potential and should be used in initial screens and/or to complement MICs only. Other in vitro methodologies can be used to evaluate the fungicidal effect of antimicrobial agents [34] . Nevertheless, the best way to demonstrate fungicidal activity is to determine the residual fungal tissue burden in neutropenic animal models of disseminated infection. Using an in vivo model of this type, it was shown that PSC and VRC exhibit fungicidal activity against Aspergillus spp. [47, 48] . Therefore, in vivo studies are necessary to confirm the fungicidal activity of PSC, VRC, and TRB against S. brasiliensis.
Even at subinhibitory concentrations, AMB and ITC were able to promote significant morphological changes in S. brasiliensis yeast cells. Drug treatment promoted changes in intracellular organelles, including formation and accumulation of electron lucent vacuoles and vesicles close to the cell wall (Fig. 3C-F) . Also, drug treatment clearly affected the cell wall, including treatment with TRB (Fig. 3I) . Increases in yeast cell wall thickness after treatment with ergosterol synthesis inhibitors has also been described for C. albicans, C. tropicalis, and Cryptococcus neoformans [49] [50] [51] . These data suggest a possible interference of ergosterol synthesis inhibitors in the composition and/or organization of the fungal cell wall. Changes in the cell wall may influence host cell response to S. brasiliensis, considering that this is the first fungal structure to contact host cells.
Further studies on S. brasiliensis susceptibility to antifungal agents should improve the "fine-tuning" of therapeutic regimens against this emergent zoonotic pathogen. Our results indicate that TRB is highly active against S. brasiliensis and might be an appropriate therapy for cutaneous and/or lymphocutaneous forms of sporotrichosis caused by S. brasiliensis. Clinical data are now required to confirm our in vitro results.
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